Scientific Publications by FDA Staff
Clin Exp Immunol 2013 Jul;173(1):131-9
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
Zhou Q, Gil-Krzewska A, Peruzzi G, Borrego F
Activation of human natural killer (NK) cells is associated with the cleavage of CD16 from the cell surface, a process mediated by matrix metalloproteinases (MMPs). In this report, we examined whether inhibition of MMPs would lead to improved NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) function. Using an in vitro ADCC assay, we tested anti-tumor function of NK cells with three different therapeutic monoclonal antibodies (mAbs) in the presence of MMPs inhibitor GM6001 or its control. Loss of CD16 was observed when NK cells were co-cultured with tumor targets in the presence of specific anti-tumor antibodies, and particularly was found on the majority of degranulating NK responding cells. Treatment with MMPs inhibitors not only prevented CD16 down-regulation, but significantly improved the quality of the responding cells, as shown by an increase in the percentage of polyfunctional NK cells that are capable of both producing cytokines and degranulation. Furthermore, MMPs inhibition resulted in augmented and sustained CD16 mediated signaling as shown by increased tyrosine phosphorylation of CD3zeta and other downstream signaling intermediates, which may account for the improved NK cell function. Collectively, our results provide a foundation for combining MMPs inhibitors and therapeutic mAbs in new clinical trials for cancer treatment.
|Category: Journal Article|
|PubMed ID: #23607800||DOI: 10.1111/cei.12095|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-04-24||Entry Last Modified: 2013-08-06|